Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)
Sweden flag Sweden · Delayed Price · Currency is SEK
1.665
+0.145 (9.54%)
Nov 4, 2026, 5:25 PM CET

STO:NEWBRY Cash Flow Statement

Millions SEK. Fiscal year is Sep - Aug.

Operating Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Aug '25 Aug '24 Aug '23 Aug '22
Net Income
--23.88-15.41-19.43-14.67
Depreciation & Amortization
-1.010.820.340.09
Asset Writedown & Restructuring Costs
-4.660.910.910.91
Stock-Based Compensation
--0.11-0.090.070.15
Other Operating Activities
-20.72-0.09-0.130.25-0.13
Change in Accounts Receivable
-8.45-7.07-11.161.26
Change in Inventory
--4-2.89-0.33-1.77
Change in Other Net Operating Assets
1.041.60.146.12-0.85
Operating Cash Flow
-19.68-12.37-23.71-23.23-15
Operating Cash Flow Growth
-----

Investing Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Aug '25 Aug '24 Aug '23 Aug '22
Sale (Purchase) of Intangibles
--2.21-2.91-0.86-24.4
Investment in Securities
---0.05--
Other Investing Activities
-0.65----
Investing Cash Flow
-0.65-2.21-2.95-0.86-24.4

Financing Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Aug '25 Aug '24 Aug '23 Aug '22
Long-Term Debt Issued
--17.31-21.78
Long-Term Debt Repaid
--1.54-2.03-0.72-7.13
Net Debt Issued (Repaid)
--1.5415.27-0.7214.64
Issuance of Common Stock
-15.3818.16-44.95
Other Financing Activities
15.11----
Financing Cash Flow
15.1113.8433.44-0.7259.59

Net Cash Flow

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Aug '25 Aug '24 Aug '23 Aug '22
Net Cash Flow
-5.22-0.746.78-24.8120.19

Free Cash Flow

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Aug '25 Aug '24 Aug '23 Aug '22
Levered Free Cash Flow
4.57-17.05-4.46-21.63-31.69
Unlevered Free Cash Flow
5.98-16.02-3.5-21.63-31.69

Additional Metrics

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Aug '26 Aug '25 Aug '24 Aug '23 Aug '22
Change in Working Capital
1.046.05-9.82-5.37-1.36